Royalty Pharma (RPRX) cash: $619M
Royalty Pharma held $619M in cash and cash equivalents on Dec 31, 2025, down 33.4% from $929M a year earlier.
From Royalty Pharma's filings with the SEC · Read the filing · RPRX stock page
Royalty Pharma cash by year
#766 of 4,171 US companies by cash · See the full ranking
| Year ended | Cash | Change |
|---|---|---|
| Dec 31, 2025 | $619M | -33% |
| Dec 31, 2024 | $929M | +95% |
| Dec 31, 2023 | $477M | -72% |
| Dec 31, 2022 | $1.7B | +11% |
| Dec 31, 2021 | $1.5B | – |
Cash of similar companies
Companies in the same industry as Royalty Pharma, by SEC industry code, with the closest cash. Each name opens the same page for that company.
| Company | Cash, latest year | Year ended |
|---|---|---|
| Zai Lab | $680M | Dec 31, 2025 |
| Immunome | $653M | Dec 31, 2025 |
| Royalty Pharma | $619M | Dec 31, 2025 |
| Wave Life Sciences | $602M | Dec 31, 2025 |
| Organon | $574M | Dec 31, 2025 |
| BridgeBio Pharma | $570M | Dec 31, 2025 |
| Innoviva | $551M | Dec 31, 2025 |
Questions and answers
What is Royalty Pharma's cash?
Royalty Pharma held $619M in cash and cash equivalents on Dec 31, 2025, down 33.4% from $929M a year earlier.
Numbers as reported in Royalty Pharma's annual and quarterly reports to the SEC (XBRL data). A year is the company's fiscal year that falls mostly in that calendar year; balances such as cash and debt are as of the date shown. Data only, not investment advice. Methodology